News and Press Releases

Neurotech signs exclusive agreement with Holy Stone Healthcare expanding distribution of Mente and support for children with autism in Taiwan

Malta and Perth, Australia – Neurotech International Limited (ASX: NTI) is pleased to announce that after two years of partnership on local tests and submissions to the Taiwan Food & Drug Administration (TFDA), Neurotech have signed Holy Stone Healthcare as the exclusive distributor in Taiwan.

Holy Stone Healthcare was established in Taipei in January 2001 and is committed to developing lifesaving therapeutics and targeted delivery technologies to improve the quality of life of patients worldwide.

The three-year agreement with Holy Stone Healthcare confirms exclusive distribution for the territory of Taiwan. The agreement is subject to successful approval from the TFDA which is anticipated to be in the first quarter of 2020. The agreement is otherwise subject to standard commercial terms for contracts of this nature.

Clinically proven Mente helps ASD children to learn to engage positively with their environment and self-regulate attention and mood. Details on Mente can be found at

Neurotech CEO, Peter Griffiths, said: “Our partnership with Holy Stone Healthcare demonstrates ourcommitment to provide the best service to our customers. I am very pleased with the collaboration between the teams and we look forward to building a significant business with Holy Stone Healthcare in Taiwan.”

Albert Wu, CEO of Holy Stone Healthcare, said: “We are excited to be moving forward with this new endeavour, as this will now give our customers access to Mente’s award-winning and clinically proven product across Taiwan.”